Cambridge, Mass.-based Infinity Pharmaceuticals Inc. appointed David Beier to its board.
Beier is a managing director of Bay City Capital, a life science-focused venture capital fund. He is also an adviser to the Parker Institute for Cancer Immunotherapy and has extensive knowledge of healthcare policy, economics and drug pricing, the company said.
Also, the biotechnology company named Marie-Louise Fjällskog as vice president of clinical development.
Fjällskog is an associate professor of Oncology at the Uppsala University, Sweden. She joins Infinity from the Novartis Institute for Biomedical Research, where she served as a clinical program leader for translational clinical oncology, and as the global lead for several immuno-oncology programs.
Infinity also promoted Suresh Mahabhashyam to the position of vice president of safety and risk management.
The company made the appointments as it advances its cancer drug IPI-549. The drug is in early stages of clinical development.
